Biography:Nguyễn Trọng Toàn
Nguyễn Trọng Toàn | |
|---|---|
| Nationality | Vietnamese |
| Known for | Lead investigator of EV71 vaccine Phase 3 trial |
| Scientific career | |
| Fields | Vaccinology, infectious diseases, clinical research |
| Institutions | Pasteur Institute of Ho Chi Minh City, University of Siena |
Nguyễn Trọng Toàn is a Vietnamese physician and vaccinologist. He is deputy director and person in charge of the Clinical Trial Center at the Pasteur Institute of Ho Chi Minh City and principal investigator of a multicountry phase 3 trial of an inactivated enterovirus 71 (EV71) vaccine published in The Lancet in 2022.[1]
Education
Nguyễn Trọng Toàn completed training in vaccinology at the University of Siena, Italy. He is listed with a University of Siena affiliation in a 2015 paper on dengue epidemiology.[2]
During his time in Siena, he trained under Rino Rappuoli together with fellow vaccinologists Dirga Sakti Rambe and Melvin Sanicas, as noted in the Pan-African Medical Journal.[3]
Career
Nguyễn Trọng Toàn joined the Pasteur Institute of Ho Chi Minh City, where he became deputy director of the Clinical Trial Center.[4][5]
He served as principal investigator of the multinational phase 3 clinical trial of an inactivated, adjuvanted EV71 vaccine, conducted in Viet Nam and Taiwan, which demonstrated efficacy of over 96% against hand, foot and mouth disease caused by enterovirus 71.[1] The results were published in The Lancet and registered under ClinicalTrials.gov identifier NCT03865238.[6]
Selected publications
- Nguyen TT, Chiu C-H, Lin C-Y, et al. "Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial." The Lancet. 399(10336):1708–1717. (2022). doi:10.1016/S0140-6736(22)00313-0.[1]
References
- ↑ 1.0 1.1 1.2 Nguyen, Trong Toan; Chiu, Cheng-Hsun; Lin, Chih-Yu; Jiang, Zhi-Min; Hu, Ying-Jui; Lin, Chia-Yin; Hu, Zhi-Qiang; Huang, Li-Min (30 April 2022). "Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet 399 (10336): 1708–1717. doi:10.1016/S0140-6736(22)00313-0. PMID 35427481. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00313-0/abstract.
- ↑ Nguyen Trong Toan (1 July 2015). "Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting". Tropical Medicine & International Health 20 (7): 840–863. doi:10.1111/TMI.12498. https://onlinelibrary.wiley.com/doi/10.1111/TMI.12498. Retrieved 19 September 2025.
- ↑ Sanicas, Melvin (2014). "Dengue: an escalating public health problem in Latin America". Pan African Medical Journal 19 (121). https://www.panafrican-med-journal.com/content/article/19/121/full/. Retrieved 19 September 2025.
- ↑ "Trung tâm Thử nghiệm Lâm sàng" (in vi). https://www.pasteurhcm.gov.vn/article/trung-tam-thu-nghiem-lam-sang-107.html.
- ↑ "Tổ chức và nhân sự" (in vi). https://crc.pasteurhcm.gov.vn/gioi-thieu/to-chuc-va-nhan-su.
- ↑ A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine. U.S. National Library of Medicine. 18 April 2022. https://clinicaltrials.gov/study/NCT03865238. Retrieved 19 September 2025.
External links
 |  |
